This generally well-conducted review concluded that positron emission tomography (PET) plus conventional imaging techniques may generally offer improved diagnostic accuracy for breast cancer recurrence compared with standard practice. PET/computed tomography (CT) appeared to show clear advantage over CT or PET alone. Despite limitations of the available evidence, the conclusions reflect the data presented. impact of prior imaging results, location of suspected metastases, previously cleared or uncleared breast cancer and standard practice being included in the evaluation.
Authors' objectives
To assess the accuracy of positron emission tomography (PET) and PET/computed tomography (PET/CT), compared with conventional diagnostic strategies or each other for the diagnosis of breast cancer recurrence.
Searching
MEDLINE and EMBASE were searched for full papers from inception to May 2009. The search strategy was reported. There were no language restrictions.
Study selection
Diagnostic accuracy studies that evaluated PET or PET/CT using a fludeoxyglucose tracer were eligible for inclusion if they used a reference standard of histological diagnosis (surgery/biopsy) and/or long-term clinical follow-up in patients with a previous diagnosis of breast cancer who had completed a course of primary treatment (whether cleared of the original disease or not). Recurrence could be local, regional or distant. Studies had to provide sufficient data to construct 2x2 tables of test performance and report the impact of tests on patient management, or report the reasons for false negative and false positive results. Studies conducted during initial breast cancer diagnosis, staging or monitoring of response to primary breast cancer treatment were excluded.
The PET camera, method of image reconstruction, contrast dose and uptake time and acquisition times varied across studies; most used visual interpretation of PET scan results. All studies used clinical follow-up as the reference standard; about 60% also used histology but seemingly not in all patients. Most studies also evaluated an alternative conventional technology, such as magnetic resonance imaging (MRI), bone scintigraphy, CT or conventional work-up. Most data were reported on a per patient basis. The reason for investigation was suspected metastases, primarily due to elevated tumour markers, symptoms or suspicious imaging results. Mean patient age, where stated, ranged from 46 to 62 years.
Studies were selected for inclusion by one reviewer; a second reviewer assessed full papers where there was doubt about inclusion.
Assessment of study quality
Study quality was conducted independently by two reviewers using an 11-point version of the QUADAS tool; disagreements were resolved by consensus.
Data extraction
Two reviewers independently extracted data to populate 2x2 contingency tables to enable calculation of sensitivity and specificity, along with 95% confidence intervals (CI). Disagreements were resolved by consensus.
Methods of synthesis
Summary receiver operating characteristic (SROC) curves were produced using a bivariate random-effects model, from which summary estimates of sensitivity and specificity with 95% CI were calculated. Patient-and lesion-based data were analysed separately; patient-based data were used as the basis for the main analysis and for the investigation of heterogeneity. A sensitivity analysis was conducted on studies that reported direct comparisons where the analysis was restricted to studies with a delay between tests of one month or less. Subgroup analysis was used to investigate the
